Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic illness marked by increasing cognitive decline and nervous system deterioration. At this time, there is no known medication that will stop the course of Alzheimer’s disease; instead, most symptoms are treated. Clinical trial failure rates for new drugs remain hi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687886/ https://www.ncbi.nlm.nih.gov/pubmed/38031028 http://dx.doi.org/10.1186/s11658-023-00504-2 |
_version_ | 1785152064849969152 |
---|---|
author | Marei, Hany E. Khan, Muhammad Umar Aslam Hasan, Anwarul |
author_facet | Marei, Hany E. Khan, Muhammad Umar Aslam Hasan, Anwarul |
author_sort | Marei, Hany E. |
collection | PubMed |
description | Alzheimer’s disease (AD) is a chronic illness marked by increasing cognitive decline and nervous system deterioration. At this time, there is no known medication that will stop the course of Alzheimer’s disease; instead, most symptoms are treated. Clinical trial failure rates for new drugs remain high, highlighting the urgent need for improved AD modeling for improving understanding of the underlying pathophysiology of disease and improving drug development. The development of induced pluripotent stem cells (iPSCs) has made it possible to model neurological diseases like AD, giving access to an infinite number of patient-derived cells capable of differentiating neuronal fates. This advance will accelerate Alzheimer’s disease research and provide an opportunity to create more accurate patient-specific models of Alzheimer’s disease to support pathophysiological research, drug development, and the potential application of stem cell-based therapeutics. This review article provides a complete summary of research done to date on the potential use of iPSCs from AD patients for disease modeling, drug discovery, and cell-based therapeutics. Current technological developments in AD research including 3D modeling, genome editing, gene therapy for AD, and research on familial (FAD) and sporadic (SAD) forms of the disease are discussed. Finally, we outline the issues that need to be elucidated and future directions for iPSC modeling in AD. |
format | Online Article Text |
id | pubmed-10687886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106878862023-11-30 Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease Marei, Hany E. Khan, Muhammad Umar Aslam Hasan, Anwarul Cell Mol Biol Lett Review Article Alzheimer’s disease (AD) is a chronic illness marked by increasing cognitive decline and nervous system deterioration. At this time, there is no known medication that will stop the course of Alzheimer’s disease; instead, most symptoms are treated. Clinical trial failure rates for new drugs remain high, highlighting the urgent need for improved AD modeling for improving understanding of the underlying pathophysiology of disease and improving drug development. The development of induced pluripotent stem cells (iPSCs) has made it possible to model neurological diseases like AD, giving access to an infinite number of patient-derived cells capable of differentiating neuronal fates. This advance will accelerate Alzheimer’s disease research and provide an opportunity to create more accurate patient-specific models of Alzheimer’s disease to support pathophysiological research, drug development, and the potential application of stem cell-based therapeutics. This review article provides a complete summary of research done to date on the potential use of iPSCs from AD patients for disease modeling, drug discovery, and cell-based therapeutics. Current technological developments in AD research including 3D modeling, genome editing, gene therapy for AD, and research on familial (FAD) and sporadic (SAD) forms of the disease are discussed. Finally, we outline the issues that need to be elucidated and future directions for iPSC modeling in AD. BioMed Central 2023-11-30 /pmc/articles/PMC10687886/ /pubmed/38031028 http://dx.doi.org/10.1186/s11658-023-00504-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Marei, Hany E. Khan, Muhammad Umar Aslam Hasan, Anwarul Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title | Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title_full | Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title_fullStr | Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title_full_unstemmed | Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title_short | Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease |
title_sort | potential use of ipscs for disease modeling, drug screening, and cell-based therapy for alzheimer’s disease |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687886/ https://www.ncbi.nlm.nih.gov/pubmed/38031028 http://dx.doi.org/10.1186/s11658-023-00504-2 |
work_keys_str_mv | AT mareihanye potentialuseofipscsfordiseasemodelingdrugscreeningandcellbasedtherapyforalzheimersdisease AT khanmuhammadumaraslam potentialuseofipscsfordiseasemodelingdrugscreeningandcellbasedtherapyforalzheimersdisease AT hasananwarul potentialuseofipscsfordiseasemodelingdrugscreeningandcellbasedtherapyforalzheimersdisease |